Any current/future new fundraising through debt or equity?

Natural Capsules has raised equity at the subsidiary level (Biogenex) to fund the API business, which included a planned total investment of ₹75 crores in two tranches (initially ₹50 crores, followed by ₹25 crores based on mutual agreement). No immediate plans for further dilution or fundraising beyond what is already public; the current minority stake in Biogenex is around 10%, potentially going up to about 35% by FY27 with private equity milestones, Natural Capsules expects to retain around 65.6%. The equity raise was primarily to manage increased project cost (from ₹96 crores to ₹130 crores

Any current/future capex/capital investment/strategic investment?

The total CAPEX for the API business has increased from an original 96 crores to about 130 crores due to cost escalations and stretched working capital cycles. The current capital raise of 75 crores (in two tranches: 50 crores initially and 25 crores later) is aimed at funding this expanded CAPEX and strengthening the balance sheet. There are no further expansion plans beyond the current API project funding; the focus is on executing the existing plan and avoiding over-leveraging. Capacity utilization targets are projected at around 50% in FY24 and expected to be cash positive by FY25. The cap

Future growth expectations in sales/revenue/volumes?

Capsule business volumes are consistently growing; last year utilized 96% of installed capacity (18 billion capsules). HPMC capsule capacity to add 3 billion, with 50% utilization expected this year. Total capsule business revenue expected to be around 2 to 2.1 times the asset base (~100 crores), indicating approx. 200+ crores sales for FY24. API business to commence small commercial sales from Q2 FY24 and ramp up from Q3. First-year revenue for API business expected around 50-65 crores. API volume/utilization expected around 50% in the first year, reaching 60% in the second year. AP

Future growth expectations in earnings/operating earnings/profits/EPS?

Capsule business expected to maintain consistent volume growth with around 96% installed capacity utilization last year; HPMC capsules capacity to be added, utilizing about 50% in FY24. Overall asset turnover target around 2 to 2.1 times in FY24, with capsule business expected around 2.5 times in coming years. API business to ramp up from FY24, with first-year revenue approximately ₹50-65 crores and expected to improve margins by year 3-4 as exports to regulated markets increase. Margins for capsule business currently at ~18%, likely to improve; API business aiming for 20%+ margins by year 3 w

Current/ Expected Orderbook/ Pending Orders?

Biogenex subsidiary has some technical grade API commitments from foreign buyers that still stand (Page 20). Letters of intent and soft commitments are in place for steroidal APIs; the company is preparing for validation and launch of small volume kilo lab to fulfill these (Page 6). Mexico contract entails incremental business of approx. 1.8 billion capsules per annum (~4 containers), expected to start from Q2 FY24, providing a significant export boost (Page 8-9). No explicit consolidated order book value mentioned, but strong indications of ongoing and upcoming contracts with domestic and exp

Natural CapsulesQ4 FY23Pharmaceuticals & Biotechnology

Natural Capsules Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹135.41Market Cap: ₹141 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Capsule business volumes are consistently growing; last year utilized 96% of installed capacity (18 billion capsules).
HPMC capsule capacity to add 3 billion, with 50% utilization expected this year.
Total capsule business revenue expected to be around 2 to 2.1 times the asset base (~100 crores), indicating approx. 200+ crores sales for FY24.
API business to commence small commercial sales from Q2 FY24 and ramp up from Q3. First-year revenue for API business expected around 50-65 crores.
API volume/utilization expected around 50% in the first year, reaching 60% in the second year.
API margins expected to improve to ~20% when 30-35% revenue comes from regulated markets (year 3 or 4).
Combined capsule and API revenues could reach 250-300+ crores in near term, with long-term API business potentially reaching 2.7 times asset turnover.
Mexico contract to add approx. 1.8 billion capsules per annum starting Q2 FY24, improving margins.
Overall growth trajectory is positive with ramp-up and capacity expansions underway.

Margin guidance

Category 3

Capsule business expected to maintain consistent volume growth with around 96% installed capacity utilization last year; HPMC capsules capacity to be added, utilizing about 50% in FY24.
Overall asset turnover target around 2 to 2.1 times in FY24, with capsule business expected around 2.5 times in coming years.
API business to ramp up from FY24, with first-year revenue approximately ₹50-65 crores and expected to improve margins by year 3-4 as exports to regulated markets increase.
Margins for capsule business currently at ~18%, likely to improve; API business aiming for 20%+ margins by year 3 with about 30-35% revenue from regulated markets.
Revenue forecast conservative for FY24 with stability in realizations and gradual volume increase; full ramp-up and better profitability expected post-FY25.
Working capital for API business expected higher (90-120 days) but manageable.
Expansion and entry into new markets (e.g., Mexico) to support top-line and bottom-line growth.

See what Natural Capsules management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Natural Capsules has raised equity at the subsidiary level (Biogenex) to fund the API business, which included a planned total investment of ₹75 crores in two tranches (initially ₹50 crores, followed by ₹25 crores based on mutual agreement).
No immediate plans for further dilution or fundraising beyond what is already public; the current minority stake in Biogenex is around 10%, potentially going up to about 35% by FY27 with private equity milestones, Natural Capsules expects to retain around 65.6%.
The equity raise was primarily to manage increased project cost (from ₹96 crores to ₹130 crores), extended working capital needs, and to deleverage the overall group balance sheet.
No additional fundraising planned beyond these tranches for the API business; the focus is on utilizing existing capacity and strengthening financials.
There are no current firm commitments for new fundraising, though infusion beyond ₹50 crores depends on future opportunities and mutual consent.

Order book

Yes

Biogenex subsidiary has some technical grade API commitments from foreign buyers that still stand (Page 20).
Letters of intent and soft commitments are in place for steroidal APIs; the company is preparing for validation and launch of small volume kilo lab to fulfill these (Page 6).
Mexico contract entails incremental business of approx. 1.8 billion capsules per annum (~4 containers), expected to start from Q2 FY24, providing a significant export boost (Page 8-9).
No explicit consolidated order book value mentioned, but strong indications of ongoing and upcoming contracts with domestic and export clients.
Some delays noted in API business scale-up but commitments remain intact; expected capacity utilization at 50% in year 1 and 60% in year 2 (Page 20).
Export orderbook and sales expected to increase from 21-22% of revenue to about 35% with the Mexico order adding significantly (Page 10).

See what Natural Capsules management said on order book — free account, 30 seconds.

Capex plans

Yes

The total CAPEX for the API business has increased from an original 96 crores to about 130 crores due to cost escalations and stretched working capital cycles.
The current capital raise of 75 crores (in two tranches: 50 crores initially and 25 crores later) is aimed at funding this expanded CAPEX and strengthening the balance sheet.
There are no further expansion plans beyond the current API project funding; the focus is on executing the existing plan and avoiding over-leveraging.
Capacity utilization targets are projected at around 50% in FY24 and expected to be cash positive by FY25.
The capsule business expansion phase is mostly completed, with capacity increased to 22 billion capsules per annum.
Future strategic investments include exploring local manufacturing opportunities in untapped export markets for capsules, such as Latin America.

Track Natural Capsules — get its next earnings analysis in your feed

How does Natural Capsules rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisNatural Capsules

Rev 2Mar 3

See where Natural Capsules sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Natural Capsules rank in Pharmaceuticals & Biotechnology?

Compare Natural Capsules against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Natural Capsules's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industries vs Divis Laboratories vs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →